{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Panobinostat+%28LBH589%29",
    "query": {
      "intervention": "Panobinostat (LBH589)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 116,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Panobinostat+%28LBH589%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T01:48:30.193Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01298934",
      "title": "LBH589 (Panobinostat) for the Treatment of Myelofibrosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
        "Post-Essential Thrombocythemia Related Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "LBH589",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ronald Hoffman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2009-09",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01298934"
    },
    {
      "nct_id": "NCT01005797",
      "title": "Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cancer",
        "Non Small Cell Lung Cancer (NSCLC)",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Panobinostat (LBH589), Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2009-11",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01005797"
    },
    {
      "nct_id": "NCT01007968",
      "title": "Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "LBH589",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2010-03",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01007968"
    },
    {
      "nct_id": "NCT03566199",
      "title": "MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "Panobinostat Nanoparticle Formulation MTX110",
          "type": "DRUG"
        },
        {
          "name": "Convection-Enhanced Delivery (CED)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sabine Mueller, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 7,
      "start_date": "2018-05-22",
      "completion_date": "2021-03-31",
      "has_results": true,
      "last_update_posted_date": "2022-02-25",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03566199"
    },
    {
      "nct_id": "NCT00556088",
      "title": "LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "LBH589, Paclitaxel, Carboplatin, Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2007-12",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2010-12-30",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00556088"
    },
    {
      "nct_id": "NCT02676323",
      "title": "Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Intrathecal Triples",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "Up to 24 Years"
      },
      "enrollment_count": 19,
      "start_date": "2016-05-03",
      "completion_date": "2018-04-09",
      "has_results": false,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02676323"
    },
    {
      "nct_id": "NCT01115036",
      "title": "A Panobinostat Presurgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "panobinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-04",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01115036"
    },
    {
      "nct_id": "NCT01693601",
      "title": "Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Mascarenhas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2013-01",
      "completion_date": "2018-05-18",
      "has_results": true,
      "last_update_posted_date": "2023-10-31",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01693601"
    },
    {
      "nct_id": "NCT01965353",
      "title": "A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma in Relapse"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2013-10",
      "completion_date": "2021-09",
      "has_results": false,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01965353"
    },
    {
      "nct_id": "NCT05324501",
      "title": "A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "MTX110",
          "type": "DRUG"
        },
        {
          "name": "Programmable pump and catheter system",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Biodexa Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2022-10-19",
      "completion_date": "2024-09-10",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-09-27T01:48:30.193Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • Durham, North Carolina",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05324501"
    }
  ]
}